Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

DiaMedica Therapeutics (DMAC) EBIT Margin (2018)

DiaMedica Therapeutics' EBIT Margin history spans 1 years, with the latest figure at 297.4% for Q3 2018.

  • For Q3 2018, EBIT Margin changed N/A year-over-year to 297.4%; the TTM value through Jun 2019 reached 1953.2%, changed N/A, while the annual FY2025 figure was 343970.0%, 26549647.0% up from the prior year.
  • EBIT Margin reached 297.4% in Q3 2018 per DMAC's latest filing.
  • In the past five years, EBIT Margin ranged from a high of 297.4% in Q3 2018 to a low of 297.4% in Q3 2018.